CEGE

Biotech & BioHealth Business Daily (PFE, MRK, BAX, BDSI, SPPI, GNBT, AVII, CEGE, BBH, GILD, LLY, SNY, BMY, OSIP)

Here are some of today's top stories affecting key drug and biotech stocks, accompanied with links through to more detailed information and analysis at BioHealthInvestor.com: New short-interest data suggest traders ...
Read Full Story »
Burning Money Pic

Many Biotechs Barely On Life Support (BPAX, CEGE, EPIX, IDMI, LJPC, NRGN, NFLD, TPTX)

We have run a watch list of companies under their own strategic review, and the number of biotech (or grouped with biotech) stocks under this description is just staggering.   We ...
Read Full Story »
cammonopoly_wideweb__430x32501
Sad_clown

The 52-Week Low Club 9/8/2008 (FRE)(FNM)(BIOD)(AUTH)(CEGE)

Freddie Mac (FRE) is one sale at $.65. A day-trader's dream, down from a 52-week high of $65.88.Fannie Mae (FNM) Almost a better deal. Sells off to $.65 from 52-week ...
Read Full Story »
Sad_clown

The 52-Week Low Club 8/27/2008 (F)(NEXM)(CEGE)(AMLN)

Ford (F) Oil moves up. Drops to $4.25 from a 52-week high of $9.24.Nexmed (NEXM) Drug trial problems. Falls to $.23 from a 52-week high of $.1.87.Cell Genesys (CEGE) Drug ...
Read Full Story »
95129c

24/7 Wall St. Most Overpaid CEO Of The Day: Cell Genesys (CEGE) CEO Stephen A. Sherwin, M.D

Cell Genesys CEO Stephen A. Sherwin, M.D made $1.3 million last year, with $577,500 coming from base salary. He did so well, in the eyes of the board, that his ...
Read Full Story »

Biotech Business Daily (AMAG, CEGE, IMCL, XOMA, TRCA)

AMAG Pharmaceuticals (NASDAQ: AMAG) has been added to the Nasdaq Biotechnology Index (NASDAQ: NBI) beginning May 19, 2008. AMAG shares up $1.26 at $39.85. The 52-week range is $38.16 to ...
Read Full Story »

Cell Genesys Scores $30 Million Premium Financing (CEGE)

Cell Genesys, Inc. (NASDAQ: CEGE) plans to offer 7.1 million shares of common stock and warrants at an equivalent of $4.22 per share with a single institutional investor, for an ...
Read Full Story »

Cell Genesys Scores Takeda Deal (CEGE)

Cell Genesys, Inc. (NASDAQ: CEGE) has announced a global alliance with Takeda Pharmaceutical Company Limited in Japan.  The companies will develop and commercialize Cell Genesys' GVAX immunotherapy for prostate cancer, ...
Read Full Story »

Major Biotech Movers (AGEN, CEGE, ENCY, IDMI, IMCL, ONXX, PFE, NTII, OXGN, PSDV, SIRT)

Antigenics Inc.  (NASDAQ: AGEN) A study for Cancer vaccine, Oncophage, for the treatment of metastatic melanoma showed mixed results this morning. Shares are down almost 7% to $2.17. The 52 ...
Read Full Story »

The Day In Biotech Stocks (January 15, 2008) (DNA, DNDN, GENZ, TTHI, LCBM, CEGE, GPCB, CGEN)

Today was a brutal day for risk stocks, and biotechs are often thought of as risky to stocks as Russian Roulette is to your head.  But Biotechs are also a ...
Read Full Story »

Short Selling Volatile Biotechs (June 2007) (DNDN, NFLD, NSTK, ADLR, ALTH, COLY, CEGE, NUVO)

Stock Tickers: DNDN, NFLD, NSTK, ADLR, ALTH, COLY, CEGE, NUVOMany of the recent biotech implosions are always interesting to see if short sellers are getting out of the way or ...
Read Full Story »

Vertex Options Active Ahead of Data Presentation

Vertex (VRTX-NASDAQ) is seeing quite a bit of trading today ahead of a data presentation tomorrow.  This one may have been very active all on its own, but since Dendreon ...
Read Full Story »

Cell Genesys Slips New Holders a Mickey

Cell Genesys, Inc. (CEGE-NASDAQ) has done what many small biotechs do that are in need of cash: sell shares in a private placement "PIPE" after a sharp stock run-up.  It ...
Read Full Story »